Results 271 to 280 of about 59,004 (282)
Some of the next articles are maybe not open access.
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Lancet, TheDavid Franklin Fiorentino, Rohit Aggarwal, Lisa Christopher-Stine +2 moreexaly